Comparison of Outcomes After Cardioversion or Atrial Fibrillation Ablation in Patients With Differing Periprocedural Anticoagulation Regimens

• Published in: Canadian journal of cardiology 2014-12, Vol.30 (12), p.1541-1546
• Main Authors: Kochhäuser, Simon, MD, Khaykin, Yaariv, MD, Beardsall, Jessica, BSc, Juta, Rasna, BSc, Hache, Philip, BSc, Trought, Kathleen, BSc, Lenton-Brym, Talia, BComm, Tsang, Bernice, MD, Pantano, Alfredo, MD, Beardsall, Marianne, ACNP, Wulffhart, Zaev, MD, Verma, Atul, MD, FHRS
• Format: Article
• Language: English
• Subjects: Aged; Anticoagulants - therapeutic use; Atrial Fibrillation - complications; Atrial Fibrillation - physiopathology; Atrial Fibrillation - therapy; Cardiovascular; Catheter Ablation - methods; Electric Countershock - methods; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Ontario - epidemiology; Retrospective Studies; Stroke - epidemiology; Stroke - etiology; Stroke - prevention & control; Treatment Outcome
• ISSN: 0828-282X; 1916-7075
• DOI: 10.1016/j.cjca.2014.09.018

Abstract Background There is a paucity of data that compare traditional vitamin K antagonist (VKA) with novel oral anticoagulant regimens in periprocedural management of cardioversion or ablation of atrial fibrillation (AF). We sought to compare outcomes of use of VKA, dabigatran (DABI), and rivaroxaban (RIVA) anticoagulation around the time of intervention. Methods We studied consecutive patients undergoing cardioversion or ablation of AF at our centre from October 2010 to October 2013. There were 3 different anticoagulation groups: warfarin (VKA), DABI, and RIVA. Safety was assessed according to number of strokes, transient ischemic attacks (TIAs), and clinically important and not important bleeding events. Results Baseline characteristics were well balanced between the groups. Average follow-up was 6 months (± 4 months). A total of 901 patients who underwent cardioversion were studied (VKA [n = 471], DABI [n = 288] and RIVA [n = 141]). In these patients there were no strokes seen during follow-up and 2 TIAs in the DABI group. Bleeding rates were low, with no significant difference between the 3 groups. A total of 680 patients who underwent ablation were studied (VKA [n = 319], DABI [n = 220] and RIVA [n = 171]). There were no strokes reported during follow-up and 3 TIAs: 2 in the VKA group and 1 in the DABI group not resulting in a significant difference between the groups. Bleeding rates were low, with no significant difference between the groups. Conclusions Overall, there was a low incidence of adverse events for all anticoagulation regimens. Warfarin, DABI, and RIVA use around the time of the procedure are safe and reasonable options for patients who undergo cardioversion or AF ablation.